FDA Approves Lilly Foundayo Oral GLP-1 Weight Loss Drug
INDIANAPOLIS, USA — April 1, 2026 In a landmark advancement in obesity treatment and metabolic disease management, Eli Lilly...
GLP-1
Advertisement
Lilly Taltz Zepbound Combo Shows Strong Phase 3b Results
Indianapolis, USA | March 28, 2026 Phase 3b Study Demonstrates Superior Clinical Outcomes Eli Lilly and Company has announced...
Sun Pharma Launches Semaglutide in India Market
MUMBAI, INDIA, March 21, 2026 Sun Pharmaceutical Industries Limited has announced the launch of its semaglutide injection under the...
GLP-1 Therapy Linked to Reduced Asthma Exacerbations
MILWAUKEE, Feb. 15, 2026 — New research presented by the American Academy of Allergy, Asthma & Immunology (AAAAI) reveals...
Novo Nordisk’s Amycretin Shows Strong Phase 2 Diabetes Results
Bagsværd, Denmark, Nov. 25, 2025 — Novo Nordisk has announced positive Phase 2 clinical trial results for amycretin, a...
Advertisements
Pfizer Finalizes Metsera Acquisition to Expand Obesity Pipeline
NEW YORK, NY — November 14, 2025 — Pfizer announced it has completed its acquisition of Metsera, Inc., strengthening...
Rhythm Pharmaceuticals Presents Four New Datasets at ObesityWeek® 2025
Boston, November 10, 2025 — Rhythm Pharmaceuticals, Inc. has announced the presentation of four pivotal datasets at ObesityWeek® 2025,...
Headline (SEO-Optimized, ≤60 characters):Actimed Secures Key Japan Patent for Muscle-Wasting Drug
London, UK – November 3, 2025 Actimed Therapeutics Ltd, a UK-based clinical-stage specialty pharmaceutical company, has announced the grant...
Pfizer Expands Obesity Pipeline with $4.9B Metsera Acquisition
NEW YORK, September 22, 2025 – In a landmark move shaping the future of obesity and cardiometabolic disease treatments,...
Advertisement
